Abstract The individual patient responses to chronic heart failure (HF) pharmacotherapies are highly variable. This variability cannot be entirely explained by clinical characteristics, and genetic variation may play a role. Therefore, this review will summarize the background pharmacogenetic literature for major HF pharmacotherapy classes (ie, β-blockers, angiotensin-converting enzyme inhibitors, digoxin, and loop diuretics), evaluate recent advances in the HF pharmacogenetic literature in the context of previous findings, and discuss the challenges and conclusions for HF pharmacogenetic data and its clinical application.
Introduction
Large clinical trials demonstrate, on average, that pharmacotherapy significantly decreases morbidity and/or mortality due to heart failure (HF). However, the individual patient responses to HF pharmacotherapies are highly variable. For example, long-term treatment with angiotensin-converting enzyme (ACE) inhibitors fails to suppress angiotensin II in as many as 15% of HF patients, and aldosterone in 38% [1] . Long-term optimal dosing of β-blockers (BBs) fails to improve left ventricular ejection fraction (LVEF) over 5% in as many as 43% of HF patients [2] . The maintenance dose of loop diuretics can range from no diuretic at all to over 400-mg furosemide equivalents [3] . Even when dosed according to age, sex, weight, renal function, and concomitant pharmacotherapy, the serum concentration of digoxin can range from 0.5 ng/mL to over 2.0 ng/mL [4] .
This wide variability in response to HF pharmacotherapies is not entirely explained by clinical characteristics, which is evident in large clinical trials where there is a similar response among most clinical subgroups [5, 6] . Genetic variation may additionally contribute to differences in drug response, the study of which is referred to as "pharmacogenetics" or "pharmacogenomics" [7] . Pharmacogenetics has proven successful in other therapeutic areas [8] , but whether it can be used to improve the application of pharmacotherapies for HF remains unproven. Therefore, this review will summarize the background pharmacogenetic literature for major classes of HF pharmacotherapy, critically evaluate the most current HF pharmacogenetic literature in this context, and discuss the conclusions and remaining challenges to clinical application of pharmacogenetics in HF. HF pharmacogenetic studies have focused on BBs much more than any other class of HF pharmacotherapy. Between 2000 and 2009, 25 studies were published. Much BB pharmacogenetic data come from small (n<400) observational cohorts of HF patients with systolic dysfunction. These studies are heterogeneous in many aspects (eg, design, size, end point, patient population, specific BB, and the genetic variants tested), making definitive conclusions difficult. A list of genetic variants associated with BB (and other HF pharmacotherapies) response is displayed in Table 1 , and the major findings are discussed herein.
Type 1 β-Adrenergic Receptor
Stimulation of the cardiac β-adrenergic receptors results in increased heart rate and contractility. The type 1 β-adrenergic receptor (protein ADRB1; gene ADRB1) is the primary target of cardiac BBs and has been the focus of most BB pharmacogenetic literature. A nonsynonymous variant in this gene, Arg389Gly, has been the moststudied (Table 1 ). This variant is common in the general population, with differences in its frequency among the races (Table 2) . Functionally, Arg389 has greater basal and agonist-stimulated activity compared to Gly389 [9] . Because Gly389 generally results in less ADRB1 sympathetic stimulation, it raises the question of whether this variant is protective in BB-naïve HF patients, and whether patients with Arg389 would receive greater benefit from BBs.
Consistent in the literature, patients possessing the Arg allele have greater LVEF improvement in response to BBs than those possessing Gly389. This comes from several prospective and retrospective studies totaling 569 patients with a variety of HF etiologies, ethnicities, and BBs [2, [10] [11] [12] . There is also evidence to support the influence of Arg389Gly on the survival benefit from BBs. The most convincing is a large (n=1,040) pharmacogenetic substudy [13] of the Beta-Blocker Evaluation of Survival Trial (BEST) [14] . Patients homozygous for Arg389 had a statistically significant improvement in survival with bucindolol compared to placebo (HR 0.62; P=0.03), whereas Gly389 carriers did not (HR 0.90; P=0.57). It is argued whether the results for bucindolol can be applied to other BBs because of its unique pharmacologic properties [15] . While these results were replicated in a prospective observational study of 201 HF patients treated with metoprolol or carvedilol [16] , other larger cohort studies have not found this association [17•] . A pharmacogenetic substudy of the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) [5] also did not find an association of Arg389Gly with survival benefit regardless of treatment (metoprolol CR/XL or placebo) [18] . However, this last study did not test BB effect within genotype groups (as was done in BEST), which may help explain the discordant results.
Type 2 β-Adrenergic Receptor
Although not the primary target of BBs, the type 2 β-adrenergic receptor (protein ADRB2; gene ADRB2) is present in myocardium, can mediate inotropic response, and, while ADRB1 is downregulated, the expression of ADRB2 is unchanged in the failing heart [19] . The moststudied variant in ADRB2 is Gln27Glu. Functionally, Glu27-containing ADRB2 is resistant to agonist-promoted desensitization compared to Gln27 [20, 21] . This suggests that Gln27 genotype is associated with less sympathetic output relative to Glu27, but the clinical pharmacogenetic literature is inconsistent. Several small studies showed a favorable LVEF response for patients carrying Glu27 compared to patients homozygous for Gln27 [22] [23] [24] . However, four other small studies failed to show a significant association [2, 11, 25, 26] , although these included β1-selective BBs, which may limit the ability to detect an interaction with ADRB2 variants. In terms of survival benefit, one study showed a survival difference by genotype among BB-treated HF patients [27] , but several large cohort studies have not demonstrated an association [17•, 25, 28] . Notably, most patients in these studies were treated with BBs, limiting the ability to examine true pharmacogenetic interactions.
Adrenergic Receptor α-2C
The α-2C adrenergic receptor is presynaptic (protein ADRA2C; gene ADRA2C), auto-inhibiting norepinephrine release. A deletion variant in ADRA2C, causing a loss of amino acids 322 to 325, results in the loss of normal autoinhibitory function and increased norepinephrine [29] . A potential interaction between ADRB1 Arg389, the ADRA2C deletion, and BB response was prospectively studied in 54 HF patients with systolic dysfunction [30••] . The deletion carriers had a greater improvement in LVEF compared to insertion homozygotes (+6% vs +1%; P= 0.045). Synergy between the ADRB1 and ADRA2C variants was supported by the magnitude of results. No association was found in 80 patients with idiopathic dilated cardiomyopathy [26] , but synergy with ADRB1 Arg389 was not tested.
G Protein-Coupled Receptor Kinase 5
The function of the G-protein receptor kinases (GRKs) is to desensitize ligand-occupied G protein-coupled receptors such as β-adrenergic receptors [31] . GRK5 is abundant in the heart and a Gln41Leu variant in this gene has been studied in vitro, with the Leu41 version more effectively desensitizing agonist-stimulated responses compared to Gln41 [32] . Because the Gln41 subtype should have more active β-adrenergic receptors, it has been proposed that Leu41 is protective in BB-naïve HF patients, but these patients may be less responsive to BB.
In an observational study of 375 African-Americans with HF, only patients homozygous for Gln41 had significantly improved transplant-free survival with BB 
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β-Blocker Pharmacogenetics: Recent Advances (Publication Year 2010 or Later)
As evidenced by the heterogeneous and observational nature of the background HF BB pharmacogenetic literature, this field is still in an early stage. The four most recent HF BB pharmacogenetic studies support previous insights, but they also demonstrate some unexpected results. A small but intriguing study in 93 HF patients [34• •] studied a panel of both pharmacokinetic and pharmacody- 
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A recent prospective study of 183 patients with HF and three previously studied genetic variants (ADRB1 [Arg389-Gly] and ADRB2 [Arg16Gly and Gln27Glu]) [24] had findings consistent with the background BB pharmacogenetic literature. The increase in LVEF after carvedilol tended to be greater in ADRB1 Arg389 homozygous (+7.8±7.6%) and heterozygous patients (+9.0±11.4%) compared to those homozygous for Gly389 (+4.1±7.6%; P= 0.0847). Patients homozygous for ADRB2 Glu27 showed a greater increase in the LVEF (+13.0±12.2%), compared to both heterozygous (+7.1±8.1%) and Gln27 homozygous patients (+8.3±11.4%; P=0.022). In multivariable analysis, cause of HF, systolic blood pressure, dose of carvedilol, and Gln27Glu genotype were significant correlates of LVEF improvement after carvedilol treatment. Notably, the ADRB1 Arg389Gly genotype was not independently informative in this dataset.
The ADRA2C insertion/deletion was tested in the genetic substudy of BEST (n=1,040) [35•] . In contrast to previous data, which indicated that the ADRA2C deletion was associated with improved LVEF response after BB, this large and adequately powered study found no differential effect on LVEF by ADRA2C genotype. Interestingly, interaction with ADRB1 Arg389Gly was not tested. Even more surprising was that this study found that the insertion allele, and not the deletion, was associated with enhanced survival benefit from BB. For the all-cause mortality end point, bucindolol produced a strong tendency toward significance (P=0.025) for a reduction in mortality by 30% in the insertion homozygotes, while there was a nonsignificant (P=0.79) 9% increase in mortality in the bucindololtreated deletion carriers. There are several possible explanations for the discrepancy in results; the previous small studies could be false-positive associations, or this could be a bucindolol-specific interaction.
A recent retrospective study of 586 HF patients examined differential pharmacogenetic interactions between carvedilol and metoprolol [36•] . The investigators combined two genotypes, ADRB1 Arg389-homozygous and ADRB2 Gln27-carrier, and compared these patients to all others in terms of time to death from any cause. They found a significant interaction between genotype group and carvedilol treatment (P=0.003), but no interaction with metoprolol (P=0.61). In patients treated with carvedilol, survival was lower for the Arg389/Gln27 group than the remaining patients (HR 2.30). Because two different variants defined these groups and the fact that one is associated with favorable BB response while the other is not, these results are difficult to put in context of the existing literature. Another concern is that there may have been negative results for metoprolol because the genotype groups were partly defined by an ADRB2 genotype, and metoprolol is β1-specific.
Overall, these more recent results, like the preexisting BB pharmacogenetic literature, are provocative but require validation in large prospective clinical trials of genetic-guided BB therapy. There is sufficient evidence to support this approach for bucindolol, as well as the currently approved agents such as metoprolol and carvedilol, and this represents the most pressing challenge for BB pharmacogenetics in HF. Other areas that remain unclear are whether additional yet unidentified genes should be the focus of future research, whether other genes are relevant to BB effectiveness, and the interaction of race with genetics. The current candidate gene list revolves strictly around the receptor, and whether other genetic loci may directly modify response or interact with the current candidates is unknown. As pointed out above, all of the current candidate variants have frequencies that differ significantly by ancestry (Table 2) , which raises the issue of both genetic and nongenetic confounding factors. Therefore, additional investigation is required for confidence in these associations and the potential application to non-Caucasian populations.
Angiotensin-Converting Enzyme Inhibitor Pharmacogenetics: Background (Literature Before 2010)
Our extensive searches revealed only six pharmacogenetic studies of ACE inhibitors in HF patients from 1998 to 2008. Like the BB literature, most of the ACE inhibitor pharmacogenetic literature in HF patients comes from small observational studies (n<200) that are heterogeneous in design. Not surprisingly, the literature has focused on the gene encoding the target of these agents, ACE. A 287-base pair insertion/deletion in intron 16 of ACE accounts for half of the variance in serum ACE levels [37] . The deletion results in significantly higher ACE levels [37] ; therefore, it was postulated that HF patients possessing the deletion would require a higher dose of ACE inhibitor to achieve the same inhibition. Most of the clinical pharmacogenetic studies are consistent with the functional effects, with respect to mean arterial pressure [38] , aldosterone escape [39] , serum ACE activity [40] , and survival [41] , but the association with LVEF is less clear [42, 43] .
In 107 patients with idiopathic dilated cardiomyopathy receiving 2.5 years of ACE inhibitor therapy [42] , the LVEF improvement was similar among ACE genotypes, but another study of 168 HF patients with systolic dysfunction [43] found that deletion carriers had a greater LVEF improvement after ACE inhibitor (deletion carriers: LVEF +8.8%; insertion homozygotes: −1.73%; P=0.01). The discordance in results may be due to populationspecific effects. In contrast, the relationship between the ACE variant and survival benefit from ACE inhibitors appears more clear based on the largest ACE inhibitor pharmacogenetic study in HF patients (n=479) [41] . There was a dose-dependent relationship between the ACE insertion/deletion and transplant-free survival. After a median follow-up of 33 months, patients on low-dose ACE inhibitors (≤ 50% of target dose) had poorer transplant-free survival associated with the deletion allele (RR for deletion homozygotes: 2.07; P=0.03), and this was exaggerated in patients who were also not receiving a BB. However high-dose ACE inhibitor (> 50% of target dose), with or without concomitant BB, eliminated the adverse effect of the ACE deletion. Although the deletion was associated with poorer transplant-free survival, it seemed that deletion homozygotes benefitted the most from ACE inhibitor and BB therapy.
Angiotensin-Converting Enzyme Inhibitor Pharmacogenetics: Recent Advances (Publication Year 2010 or Later)
There is little ACE inhibitor pharmacogenetic literature recently, with only one study published [44•] within the past 2 years. This study is consistent with the previous findings on survival, and extends this to HF patients with preserved LVEF. This study enrolled 285 HF patients followed for about 7 years for all-cause mortality [44• ]. The deletion allele was associated with higher mortality in patients not receiving an ACE inhibitor (HR 2.23; P= 0.008), but this impact was reduced among patients receiving an ACE inhibitor (HR 1.64; P=0.20). Acknowledging the limitation that the ACE pharmacogenetic literature comes entirely from observational cohorts, the sum of these data suggests that HF patients that are deletion carriers may need higher-dose ACE inhibition to achieve similar outcomes compared to insertion homozygotes. While at this point it seems unlikely that renewed interest will come to ACE inhibitor pharmacogenetics, a variety of intriguing points remain, such as whether other genes are important, whether adverse events (eg, angioedema and hyperkalemia) can be predicted based on genetics, or whether genetics can help guide combinations of therapies (eg, BB+ACE inhibition vs BB alone vs ACE inhibition alone).
Pharmacogenetics of Loop Diuretics: Background (Literature Before 2010)
There have been six studies investigating the association between genetic variation and loop diuretic response published from 2004 to 2008. Five of the studies were performed in healthy volunteers (HV), and one small study included patients with HF. Collectively, these studies demonstrated that genetic variants involved in the metabolism (CYP2C9), uptake (SLC22A11 and SLCO1B1), and action (SLC12A3, SCNN1B, and SCNN1G) of the loop diuretics can influence their pharmacokinetics and pharmacodynamics.
In 10-mg torsemide single-dose HV studies, the decreased function CYP2C9*3 allele had significant effects on torsemide pharmacokinetics and modest effects on pharmacodynamics [45] . The total oral clearance of torsemide was about threefold lower in CYP2C9 *3/*3 patients compared to *1/*1 patients. Sodium and chloride excretion were about 25% higher in carriers of one CYP2C9*3 allele after torsemide administration [45] . HVs homozygous for the two most frequent haplotypes of SLC22A11 (gene encoding the organic anion transporter 4 [OAT4]) had an 80% difference in the renal clearance of torsemide [46] , and HVs homozygous for 521T and heterozygous and homozygous for 521C in SLCO1B1 (gene encoding the organic anion transporting polypeptide 1B1 [OATP1B1]) had torsemide oral clearances estimated as 62, 46, and 41 mL/min, respectively (P<0.001) [47] . Taken together, variants in CYP2C9 and the genes for OATP1B1, OAT1, and OAT4 explain nearly 50% of torsemide pharmacokinetic variation [47] .
Three renal sodium reuptake transporters are the primary targets of the loop diuretics: NKCC2 (gene SLC12A1), NCC (gene SLC12A3), and ENaC (genes SCNN1A, SCNN1B, and SCNN1G) [48] . A three-period crossover study was performed in 97 HVs using single oral doses of bumetanide (2 mg), furosemide (80 mg), and torsemide (10 mg) to evaluate the influence of variation in these on diuretic response [48] . There were three significant associations with the 24-hour excretion, and this was consistent among the three loop diuretics: 1) patients homozygous for Ala264 in SLC12A3 excreted an average 32% more chloride and 42% more potassium compared to those homozygous for Gly264; 2) patients homozygous for the most frequent haplotype in SCNN1B excreted 24% more volume, 13% more sodium, and 13% more chloride compared to patients without the most frequent haplotype; and 3) patients homozygous for G4 at a synonymous C4G substitution in SCNN1G excreted 23% less volume and 24% less calcium compared to patients homozygous for the C4 allele.
The loop diuretic pharmacogenetic data discussed to this point involve single-dose studies performed in HVs, but the data in HF patients receiving steady-state dosing appear consistent with the HVs. In a small, open-label, pharmacokinetic study of 24 patients receiving stable doses of 10-mg daily torsemide (n=18 with arterial hypertension and n=6 with HF) [49] , the primary end point was area under the plasma concentration-time curve during the 24-hour dosing interval at steady state (AUC 24,ss ). CYP2C9 genotype, SLCO1B1 genotype, and sex independently predicted AUC 24,ss . Similar to HVs, HF patients with the CYP2C9 *1/*3 genotype had a mean AUC 24,ss 46% greater than those with the *1/*1. Patients heterozygous for T521C in SLCO1B1 had a 38% increase in AUC 24,ss compared to patients homozygous for 521T (no 521C homozygotes found).
Pharmacogenetics of Loop Diuretics: Recent Advances (Publication Year 2010 or Later)
Despite the interesting associations above, whether these differences in pharmacokinetic parameters across genotypes translate into clinically meaningful differences in drug effectiveness in patients with HF remains unknown. One recent study attempted to answer this question. This was a randomized, single-blind, three-arm, triple-crossover study in 95 HVs [50•] who received a single oral dose of bumetanide (2 mg), furosemide (80 mg), and torsemide (10 mg) at 2-week intervals. Together, eight genetic variants had an impact of 20%, 15%, 10%, and 23% on the variation in the urinary excretion of sodium, volume, potassium, and calcium. Thus, genetic variation seems to importantly impact not only pharmacokinetics of loop diuretics but also their clinical effect. The incorporation of genetic data may help in determining diuretic dosing, though the clinical situation where this would be necessary is not obvious. Important questions that remain to be addressed are whether genetic variation can predict worsening renal function associated with chronic diuretic therapy, or even the risk of recurrent hospitalization.
Digoxin Pharmacogenetics: Background (Literature Before 2010)
Digoxin is a narrow therapeutic index drug, with recommended serum digoxin concentration (SDC) being 0.7 to 0.9 ng/mL [51] . The pharmacokinetics, and therefore SDC, may be affected by genetic variation. Indeed, a study in monozygotic and dizygotic twins estimated the genetic component contributing to digoxin AUC 0-12 to be 89% [52] . The seminal paper investigating the influence of genetic variation on digoxin pharmacokinetics was published in 2000 [53] , and it has been followed by 12 more studies with inconsistent results.
Most of the digoxin pharmacogenetic literature has focused on a common C3435T variant in ABCB1 (Table 2) . ABCB1 encodes for P-glycoprotein (P-gp), an efflux protein for which digoxin is a substrate. In the seminal paper, patients homozygous for 3435T (n=5) had over twofold lower expression of P-gp in the duodenum compared to patients homozygous for 3435C (n=6; P=0.056). As would be expected, patients homozygous for 3435T had 38% higher SDC than patients homozygous for 3435C (P=0.006). Acknowledging this small sample size, these results have been consistent with six subsequent studies in HVs [54] [55] [56] [57] [58] [59] , as well as a population-based study of 195 "digoxin-users" (HF status not reported) [60•] . Despite this seemingly consistent line of evidence, some contrasting data has arisen. Another study of 39 HF patients found no difference in steady-state SDC among C3435T genotypes, which was consistent with another study in 50 HVs [61] as well as a meta-analysis [62] . Unfortunately, this small HF study did not control for differences in renal function, which can vary widely among patients with HF.
Overall, the preponderance of evidence favors an impact of genetic variation on digoxin pharmacokinetics. Despite this, whether the difference in digoxin pharmacokinetics by C3435T genotypes is clinically meaningful in patients with HF is not established. Adding to this complexity is that the association of the C3435T genotype with digoxin pharmacokinetics may depend on ethnicity. Two studies in Japanese patients found a reverse association, in which the 3435C genotype had higher SDC [63, 64] .
Digoxin Pharmacogenetics: Recent Advances (Publication Year 2010 or Later)
Only a single study, with a unique postmortem SDC design (n=112), was identified in our searches regarding digoxin pharmacogenetics in the past 2 years. This study's results are consistent with the notion that ABCB1 3435T confers higher SDC [65•] , but adds to the existing data by suggesting that the interactions with C3435T may be sexspecific. There was a relationship between the frequency of 3435T allele and postmortem SDC, but surprisingly, the results were driven by females. If true, this relationship could help explain previous data demonstrating higher mortality in women treated with digoxin versus placebo due to differences in SDC between women and men [66] . Validation of this finding in adequately sized, prospective, sex-specific cohorts is needed. If validated, one could envision using genotype to identify patients at higher risk of toxicity who should not receive digoxin, receive reduced dosing, or receive more intense drug-level monitoring.
Conclusions
While there are many gaps in the HF pharmacogenetic knowledge base, limiting its current clinical application, we have already learned a great deal from the relatively modest body of HF pharmacogenetic literature. For example, while genetic variant functional/mechanistic effects need to be demonstrated to truly establish causation, this is not sufficient because these associations do not always translate into clinical effects. Another important insight is that there can be synergy or interaction between multiple genetic variants, as is the case for ADRB1 Arg389Gly and ADRA2C insertion/deletion with LVEF response to BBs. Even more daunting is the complexity and specificity of some pharmacogenetic associations. HF pharmacogenetic associations may be race-specific (eg, GRK5 Gln41Leu and BB response in African-Americans), dose-specific (eg, ACE insertion/deletion and low-and high-dose ACE inhibitors), sex-specific (eg, ABCB1 C3435T and SDC in women), and drug-specific (eg, ADRB1/ADRB2 and response to carvedilol but not metoprolol).
Despite the fact that pharmacogenetics has been in existence for decades, the number of studies on HF therapies are still relatively small and we are yet in the early stages of this part of the field. This foundation has yielded the important insights above and also provided numerous improvements in approach in terms of both genotyping and analysis. This has set the stage for accelerated advances moving forward. At this point, some of the key knowledge gaps include 1) lack of foundational pharmacogenetic data regarding angiotensin-receptor blockers, aldosterone antagonists, and hydralazine/isosorbide dinitrate; 2) investigation into acute or intravenous HF pharmacotherapies; and 3) better understanding of multivariant/multidrug combinations on pharmacogenetics. Most importantly, prospective intervention clinical trials where a genetic-guided approach is compared to empiric therapy are broadly needed to make real progress. These are required to validate proposed associations and establish that a specific response to the genetic information can improve treatment outcomes. Because HF is a fatal and common disease requiring polypharmacy, any information (even genetic) that could improve HF pharmacotherapies would give profound patient and public health benefit.
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